Summary. Background: Acquired von Willebrand syndrome (AVWS) is associated with lymphoproliferative disorders, including monoclonal gammopathy (MG) of undetermined significance (MGUS) and multiple myeloma. Patients commonly present with significant bleeding complications that are difficult to manage, owing to a markedly reduced von Willebrand factor (VWF) half-life. Objectives: To investigate the use of the immunomodulatory drug lenalidomide in two patients with severe refractory bleeding caused by AVWS associated with MGs. Results: In both patients, lenalidomide treatment resulted in significant clinical improvement, and marked increases in plasma VWF antigen (VWF:Ag) and VWF ristocetin cofactor levels. This normalization in plasma VWF levels was sustained for > 2 years in both patients. Further-more, in one patient, plasma VWF levels remain normal for at least 14 months following discontinuation of lenalidomide treatment. To investigate the molecular mechanisms underlying these observations, VWF propeptide (VWFpp)/VWF:Ag ratios were analyzed to assess VWF clearance. At enrolment, plasma VWFpp/VWF:Ag ratios were significantly elevated in both patients. Importantly, lenalidomide treatment resulted in normalization of VWFpp/VWF:Ag ratios in both patients. These novel data suggest that lenalidomide functions to attenuate enhanced VWF clearance in AVWS. Interestingly, in a patient with MGUS, lenalidomide treatment was associated with a significant increase in plasma VWF levels, despite no major change in paraprotein level. Conclusions: Collectively, our findings suggest that lenalidomide constitutes a novel therapeutic option for the management of AVWS associated with MG. The biological mechanism(s) through which lenalidomide causes a sustained increase in plasma VWF levels in AVWS independently of paraprotein level requires further study, but is Introduction Acquired von Willebrand syndrome (AVWS) is an uncommon bleeding disorder that results from reduced plasma von Willebrand factor (VWF) activity in individuals with no personal or family history of von Willebrand disease. To date, > 700 cases of AVWS have been described [1] [2] [3] [4] . AVWS often occurs in association with specific underlying conditions. Previous studies have reported 30-50% of AVWS cases to be associated with underlying lymphoproliferative disorders (LPDs) [1] [2] [3] , although recognition of AVWS in patients with structural cardiac disease is increasing [5] [6] [7] . Among the LPDs, monoclonal gammopathy (MG) of undetermined significance (MGUS) represents the most frequent association [1, 8, 9] . Although the pathologic mechanisms underlying AVWS are heterogeneous and remain poorly understood, circulating VWF-specific antibodies have been demonstrated in patients with LPDs [10] . Binding of these antibodies to circulating VWF results in a markedly reduced plasma half-life. Antibody-independent enhanced VWF clearance has also been observed in some cases of LPDassociated AVWS, owing to selective adsorption of high molecular weight VWF multimers directly onto the surface of tumor cells or platelets [11] [12] [13] [14] .
The management of bleeding complications in AVWS frequently poses a significant clinical challenge. Desmopressin (DDAVP) and VWF-containing concentrates can be useful in boosting plasma VWF levels, but their efficacy may be limited in AVWS patients with markedly enhanced clearance [15, 16] . Intravenous immunoglobulin (IVIg) is often effective for the treatment of IgG MGUS-associated AVWS [16, 17] . In refractory cases, treatment of the underlying LPD has been associated with AVWS remission. Immunomodulatory drugs (IMiDs), including lenalidomide (Revlimid; Celgene, Uxbridge, UK), have become established in the treatment of multiple myeloma. In this study, we report the first use of lenalidomide as a novel treatment option for patients with refractory AVWS associated with MG.
Clinical cases and methods
Patient A is a 75-year-old male who initially presented with recurrent, severe epistaxis, necessitating hospitalization on two occasions. On one occasion, severe epistaxis had persisted for 3 days prior to attendance. Despite nasal packing, the bleeding continued, resulting in hypotension and syncope, and ultimately requiring a 4-unit red blood cell transfusion. Despite multiple otorhinolarygology reviews, no local cause for the patient's epistaxis was identified. He was subsequently diagnosed with AVWS (VWF antigen [VWF:Ag] level of 0.19 IU mL À1 ; VWF ristocetin cofactor [VWF:RCo] level of 0.14 IU mL À1 ), which was associated with an underlying MGUS and a small IgG paraprotein (3.8 g L À1 ) ( Table 1 ). In view of his epistaxis, he was treated with DDAVP (0.3 lg kg À1 , intravenous). However, his plasma VWF levels were not significantly improved following DDAVP treatment (pre-DDAVPplasma VWF:RCo level of < 0.1 IU mL À1 ; 1 h post-DDAVPplasma VWF: RCo level of 0.3 IU mL À1 ; 4 h post-DDAVPplasma VWF:RCo level of < 0.1 IU mL À1 ). Subsequently, he also received IVIg (0.4 g kg À1 daily for five consecutive days). Unfortunately, this treatment was associated with severe nausea and headache. Finally, the patient was also treated with plasma-derived VWF concentrate (Haemate P). However, the infused Haemate P was associated with rapid clearance (t 1/2 < 1 h), and again had limited efficacy in managing his bleeding. In addition to his ongoing epistaxis, he subsequently presented with significant persistent frank hematuria, which was also refractory to standard treatments. A possible malignant prostatic lesion was identified, requiring biopsy. Given the patient's significant and refractory bleeding phenotype, lenalidomide was initiated at a dose of 25 mg daily. Lenalidomide treatment was administered in 28-day cycles (21 days of treatment followed by a 7-day break). Following eight cycles, the lenalidomide dose was reduced to 15 mg daily. Patient B is a 63-year-old male who also presented with severe recurrent bleeding complications, including recurrent epistaxis, and culminating in a sight-threatening retinal bleed. He was diagnosed with AVWS (VWF:Ag level of 0.1 IU mL À1 ; VWF:RCo level of < 0.1 IU mL À1 ) resulting from IgA smoldering myeloma (paraprotein level of 26.9 g L À1 ) ( Table 1) . Hemorrhagic episodes responded poorly to DDAVP, IVIg and VWF-containing concentrate. Following DDAVP treatment, only a small transient increase in VWF:RCo levels was observed (pre-DDAVPplasma VWF:RCo level of < 0.1 IU mL À1 ; 1 h post-DDAVPplasma VWF:RCo level of 0.3 IU mL À1 ; 4 h post-DDAVPplasma VWF:RCo level of < 0.12 IU mL À1 ). Markedly enhanced clearance was also apparent following infusion of VWF-containing concentrate. Because of rising plasma viscosity (plasma viscosity of 7.11 cP; paraprotein level of 15.5 g L À1 ) and increased bleeding, four cycles of plasmapheresis were performed. However, there was no significant improvement in either VWF levels (VWF:Ag level of 0.11 IU mL À1 ; VWF:RCo level of < 0.1 IU mL À1 ) or bleeding phenotype. Consequently, lenalidomide treatment was commenced in an effort to manage the patient's ongoing bleeding episodes. In view of his higher paraprotein burden, dexamethasone 40 mg weekly was used concomitantly with lenalidomide 25 mg daily (21 days of treatment followed by a 7-day break) for the first eight cycles.
Prior to commencement of of lenalidomide treatment, both patients were fully counseled by two independent consultant hematologists who subspecialize in the management of such patients. During these consultations, the potential risks and side effect profile of lenalidomide were discussed in detail, including the risks of secondary malignancies, myelosuppression, myelodysplasia, infection, gastrointestinal disturbance, thrombosis, and fatigue. Informed consent was received from both patients prior to the commencement of of lenalidomide treatment. Plasma VWF:Ag and VWF:RCo assays were performed throughout and after treatment. All VWF assays were performed on plateletpoor plasma collected in sodium citrate (0.106 M), and compared with a reference of pooled normal plasma. VWF:Ag levels were measured with a latex particle enhanced immunoturbidimetric assay (HemosIL VWF antigen assay; Instrumentation Laboratory, Milan, Italy) on an automated coagulometer (ACL Top 3G, Instrumentation Laboratory). VWF:RCo levels were determined according to standard platelet agglutination on a Sysmex CS2100i Analyser (Siemens Healthcare, Marburg, Germany). Finally, plasma VWF propeptide (VWFpp) levels were also determined as previously described by use of the mAbs CLB-Pro 35 and CLB-Pro 14.3-HRP (Sanquin, Amsterdam, The Netherlands) [18] .
Results and discussion
Several treatment options exist for smoldering and aggressive myeloma that can reduce the paraprotein burden and may improve AVWS. In contrast, treatment options for MGUS-associated AVWS are much more limited. Lenalidomide and its analog thalidomide are IMiDs that are widely used in the treatment of MGs [19] . Although there are no previous reports regarding the use of IMiDs in AVWS, we observed that lenalidomide treatment was associated with significant clinical improvement in two patients with refractory bleeding and AVWS secondary to MG. After an initial lag period, plasma VWF:Ag and VWF:RCo levels significantly increased in patient A (Fig. 1A) . Plasma VWF:Ag levels were corrected to within the normal range within 3 months of commencement of lenalidomide treatment. Plasma VWF:RCo levels also increased during the first 3 months of treatment, and were within the normal range by 6 months. At this point, prostate biopsy was performed, and confirmed a prostate adenocarcinoma (Gleason score of 9). Following a formal multidisciplinary team review, patient A elected to receive local radiotherapy. In discussion with the patient, the associated risks of developing radiation proctitis and bleeding complications were outlined. Furthermore, the potential side effects of continuing lenalidomide treatment in this context were reiterated. On the basis of these discussions, the patient chose to continue with lenalidomide treatment until his radiotherapy was completed. Despite the fact that the dose of lenalidomide was reduced to 15 mg daily after eight cycles, owing to Grade 2 neutropenia, VWF:Ag and VWF:RCo levels remained within the normal range. Plasma VWF levels remained within the normal range for at least another 14 months after discontinuation of lenalidomide.
Similarly, although patient B had a much higher initial paraprotein burden, plasma VWF:Ag and VWF:RCo levels both significantly increased within 3 months of commencement of combined lenalidomide and dexamethasone treatment (Fig. 1B) . Following eight cycles, dexamethasone was discontinued, and the lenalidomide dose was reduced to 15 mg once daily. Nevertheless, plasma VWF levels were sustained within the normal range for a further 18 months. Subsequently, following a decrease in plasma VWF levels and a concomitant increase in IgA paraprotein levels, the lenalidomide dose was increased back to 25 mg. On this occasion, the lenalidomide dose alteration resulted in rapid but transient increases in plasma VWF:Ag and VWF:RCo levels. Collectively, these data demonstrate that lenalidomide constitutes a novel therapeutic option in patients with AVWS secondary to MGs. Moreover, in some AVWS patients, lenalidomide can produce a sustained increase in plasma VWF levels that persists even following cessation of the IMiD treatment.
The biological mechanism or mechanisms through which lenalidomide corrects plasma VWF levels in patients with AVWS secondary to MGs remain unknown. Importantly, however, previous studies have reported that IMiD treatments are associated with significantly increased plasma levels of VWF and factor VIII [20, 21] . In addition, the use of IMiDs in patients with multiple myeloma has also been associated with a significantly elevated risk of venous thrombosis [22, 23] . Interestingly, we observed clear differences in the time course of VWF response in our two patients with MGUS and myeloma, respectively. In patient A, peak plasma VWF levels (VWF:Ag level of 1.28 IU mL À1 ; VWF:RCo level of 1.14 IU mL À1 ) were not achieved until 16 months following commencement of lenalidomide treatment. Thereafter, plasma VWF levels were sustained despite cessation of lenalidomide treatment. In contrast, in patient B, markedly elevated peak VWF levels (VWF:Ag level of 1.89 IU mL À1 ; VWF:RCo level of 1.65 IU mL À1 ) were observed within 10 months of commencement of lenalidomide treatment. However, subsequently, there were progressive decreases in both VWF:Ag and VWF:RCo levels, despite ongoing lenalidomide treatment. Furthermore, a clear inverse relationship between plasma VWF and paraprotein levels was observed in patient B (Fig. 1B) . Critically, however, despite the sustained increase in VWF levels observed in patient A, the low plasma paraprotein levels remained largely unchanged. To further investigate the molecular mechanisms underlying the effects of lenalidomide on plasma VWF levels, we studied VWFpp levels and VWFpp/VWF:Ag ratios in both patients (Fig. 1C,D) . There was little change in the VWFpp levels in either patient before and after six cycles of lenalidomide treatment (patient Abefore, 0.74 U mL À1 , and after, 1.09 U mL À1 ; patient Bbefore, 1.48 U mL À1 , and after, 1.54 U mL À1 ), demonstrating that the rates of VWF synthesis and secretion were not significantly increased. In contrast, the VWFpp/VWF:Ag ratio was significantly increased at baseline in both patients (3.5 and 14.8), suggesting that enhanced clearance was responsible for the reduction in plasma VWF levels. Following six cycles of lenalidomide treatment, the elevated VWFpp/VWF:Ag ratios were significantly corrected in both patients (1.14 and 2.23, respectively).
Overall, these data support the hypothesis that lenalidomide treatment significantly attenuates the rapid clearance of VWF in patients with AVWS resulting from MGs. Of particular interest, however, is the fact that this effect on VWF clearance in patient A was independent of any significant reduction in the plasma paraprotein level, and was sustained even following cessation of lenalidomide treatment.
It is important to note that lenalidomide is not licensed for the treatment of MGUS or AVWS, and has a significant side effect profile. Therefore, patients must be counseled regarding these potential side effects prior to commencement of treatment, so that an informed decision to consent can be made.
In conclusion, our novel findings suggest that lenalidomide may constitute a novel therapeutic option for patients with AVWS associated with MGs. In particular, lenalidomide may be specifically useful for patients with significant bleeding complications that have proved refractory to standard therapeutic approaches. Further, adequately powered, clinical trials will be required to define the efficacy and safety of lenalidomide in patients with AVWS. 
